NON-SMALL CELL LUNG CANCER STAGE III
Clinical trials for NON-SMALL CELL LUNG CANCER STAGE III explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER STAGE III trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER STAGE III, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to make inoperable lung cancer operable
Disease control Recruiting nowThis phase 2 trial tests whether giving chemotherapy plus the immunotherapy drug cemiplimab (Libtayo) before surgery can shrink tumors enough to allow surgical removal in people with stage 3 non-small cell lung cancer that has spread to certain lymph nodes (N3). About 21 particip…
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Cancer-Fighting virus plus chemo and immunotherapy takes on lung cancer in new trial
Disease control Recruiting nowThis study tests a new approach for people with advanced lung cancer whose disease got worse after initial treatment. It combines an injected virus (Olvi-Vec) that targets cancer cells, followed by chemotherapy and an immunotherapy drug, and compares it to standard chemotherapy a…
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Phase: PHASE2 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill targets Hard-to-Treat lung cancer in patients who Can't have standard therapy
Disease control Recruiting nowThis phase 2 trial is testing a daily pill called sotorasib (AMG510) in people with stage III lung cancer that has a specific genetic change (KRAS G12C) and cannot be treated with standard chemotherapy plus radiation. The study will enroll about 19 participants to see if the drug…
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Phase: PHASE2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Blood test guides new attack on lung cancer return
Disease control Recruiting nowThis study uses a blood test to detect tiny amounts of cancer DNA left after standard treatment for early-stage non-small cell lung cancer. People whose blood shows this leftover cancer are at higher risk of the cancer coming back. The study tests whether the drug durvalumab can …
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Breathing new life: exercise program aims to ease shortness of breath in advanced lung cancer
Symptom relief Recruiting nowThis study looks at whether pulmonary rehabilitation—a program of exercise and breathing techniques—can improve breathing, fatigue, and quality of life for people with advanced non-small cell lung cancer. Half of the 85 participants will do an 8-week rehab program, while the othe…
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
New radiation technique aims to protect heart in thoracic cancer patients
Knowledge-focused Recruiting nowThis study tests whether a newer, MRI-guided radiation method (MRgART) is gentler on the heart than standard radiation (LINAC) for people with lung, esophageal, or other chest cancers. About 60 adults will receive radiation and have their heart function checked via MRI and blood …
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Real-World study tracks immune response in lung cancer patients after standard treatment
Knowledge-focused Recruiting nowThis observational study follows 50 people with stage III non-small cell lung cancer who have already received chemo-radiotherapy and are about to start immunotherapy with durvalumab. Researchers will look at how the immune system responds and whether that relates to survival. Th…
Matched conditions: NON-SMALL CELL LUNG CANCER STAGE III
Sponsor: Fundación GECP • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC